James K. Fong - 24 Jan 2023 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
EVP & Chief Commercial Officer
Signature
Jim Fong
Issuer symbol
N/A
Transactions as of
24 Jan 2023
Net transactions value
-$505,110
Form type
4
Filing time
26 Jan 2023, 15:49:57 UTC
Previous filing
11 Mar 2022
Next filing
16 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $94,890 +100,000 +2805% $0.9489* 103,565 24 Jan 2023 Direct
transaction CTIC common stock Sale $600,000 -100,000 -97% $6.00 3,565 24 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Award $0 +288,000 $0.000000 288,000 19 Feb 2019 Common Stock 288,000 $0.9489 Direct F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -100,000 -35% $0.000000 188,000 24 Jan 2023 Common Stock 100,000 $0.9489 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.